Griffin Capital Essential Asset REIT Completes Acquisition

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Griffin Capital Essential Asset REIT Completes Acquisition of Signature Office REIT

EL SEGUNDO, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Griffin Capital Corporation ("Griffin Capital") announced today, on behalf of Griffin Capital Essential Asset REIT, Inc. ("GCEAR"), the completion of the merger with Signature Office REIT, Inc. ("Signature"), forming a combined company with a total capitalization of approximately $3.0 billion comprised of 70 properties in 20 states and consisting of approximately 15.9 million square feet. Under the terms of the merger agreement, each share of Signature common stock has been converted into 2.04 newly issued shares of GCEAR common stock.

As part of the merger, GCEAR acquired a real estate portfolio comprised of 15 buildings located on 13 properties, encompassing over 2.6 million square feet, situated across eight states. The portfolio consists mostly of business essential properties for tenants that include, among others, State Farm Mutual Auto Insurance Company, GE Oil & Gas, Inc., Time Warner Cable Southeast, LLC, and NEC Corporation of America. The addition of these assets is highly complementary to GCEAR's existing portfolio, which is primarily composed of single-tenant office and industrial real estate assets that serve as business essential facilities for a diverse and robust roster of blue-chip, Fortune 500 companies.

Commenting on the merger, Kevin Shields, Griffin Capital's Chairman and Chief Executive Officer, stated, "We are excited to welcome the Signature stockholders to GCEAR. This high-quality diversified portfolio adds depth and breadth to GCEAR, which now has a total capitalization of approximately $3 billion. The additional scale provides us and our stockholders, including the former Signature stockholders, with greater potential to execute a value-enhancing liquidity event."

Michael J. Escalante, Griffin Capital's Chief Investment Officer, added, "With this acquisition, we have added a number of properties that serve as business essential assets for tenants in complementary areas for our portfolio. These new properties include key regional and national operating facilities that we believe provide steady cash flow and greater geographic diversity."

Robert A. Stanger & Co. acted as financial advisor for GCEAR, and Baker, Donelson, Bearman, Caldwell & Berkowitz, PC served as legal advisor for GCEAR. Eastdil Secured, LLC a division of Well Fargo Securities, LLC acted as financial advisor for Signature.

About Griffin Capital Essential Asset REIT and Griffin Capital Corporation

Griffin Capital Essential Asset REIT, Inc. is a publicly registered non-traded REIT with a portfolio that currently includes 70 office and industrial distribution properties totaling approximately 15.9 million rentable square feet. The REIT's sponsor is Griffin Capital Corporation ("Griffin Capital"), a privately-owned real estate company headquartered in Los Angeles. Led by senior executives each with more than two decades of real estate experience collectively encompassing over $20 billion of transaction value and more than 650 transactions, Griffin Capital and its affiliates have acquired or constructed approximately 39 million square feet of space since 1995. Griffin Capital and its affiliates manage, sponsor and/or co-sponsor a portfolio consisting of approximately 24.2 million square feet of space, located in 28 states, representing approximately $4.0 billion in asset value. Additional information about Griffin Capital is available at  www.griffincapital.com .

This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as "may," "will," "expect," "intend," "anticipate," "estimate," "believe," "continue," or other similar words. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from the expectations, intentions, beliefs, plans or predictions of the future expressed or implied by such forward-looking statements. These risks, uncertainties and contingencies include, but are not limited to: uncertainties relating to changes in general economic and real estate conditions; uncertainties relating to the implementation of our real estate investment strategy; uncertainties relating to financing availability and capital proceeds; uncertainties relating to the closing of property acquisitions; uncertainties relating to the public offering of our common stock; uncertainties related to the timing and availability of distributions; and other risk factors as outlined in the REIT's prospectus, as amended from time to time. This is neither an offer nor a solicitation to purchase securities.

Jennifer Nahas Vice President, Marketing Griffin Capital Corporation Office Phone: 949-270-9332 Cell Phone: 949-433-6860

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading